Pdt Partners, LLC Tricida, Inc. Transaction History

Pdt Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $43,673 - $69,795	5,132 Added 20.86%	29,732 $312,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $46,334 - $67,011	6,304 Added 34.46%	24,600 $202,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $74,582 - $170,168	-17,800 Reduced 49.31%	18,296 $175,000
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $153,998 - $200,717	-43,258 Reduced 54.51%	36,096 $167,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $28,428 - $38,935	-7,197 Reduced 8.32%	79,354 $343,000
Q1 2021 May 17, 2021	SELL	$4.52 - $7.8 $216,666 - $373,893	-47,935 Reduced 35.64%	86,551 $458,000
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $41,340 - $89,491	9,460 Added 7.57%	134,486 $948,000
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $777,076 - $2.44 Million	90,780 Added 265.08%	125,026 $1.13 Million
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $96,590 - $143,678	-4,554 Reduced 11.74%	34,246 $941,000
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $576,859 - $1.19 Million	31,300 Added 417.33%	38,800 $854,000
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $222,000 - $327,825	7,500 New	7,500 $283,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.